From: Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
 | No. | Infection | Thrombocytopenia | Neutropenia | Anemia | Asthenic conditions | Nausea and vomiting |
---|---|---|---|---|---|---|---|
PTCL subtypes | |||||||
  PTCL NOS | 69 | 4 | 20 | 17 | 4 | 7 | 4 |
  AITL | 27 | 4 | 30 | 22 | 7 | 4 | 0 |
  ALK-1–negative ALCL | 21 | 5 | 24 | 14 | 0 | 5 | 5 |
  Other | 14 | 21 | 31 | 36 | 14 | 0 | 7 |
Age | |||||||
  < 65 years | 86 | 6 | 23 | 22 | 6 | 4 | 6 |
  ≥ 65 years | 45 | 7 | 22 | 16 | 4 | 9 | 0 |
International Prognostic Index score | |||||||
  0-1 | 31 | 3 | 19 | 13 | 10 | 0 | 7 |
  ≥ 2 | 100 | 7 | 24 | 22 | 4 | 7 | 3 |
Prior systemic therapies | |||||||
  < 3 | 83 | 6 | 15b | 21 | 8 | 5 | 5 |
  ≥ 3 | 48 | 6 | 38b | 19 | 0 | 6 | 2 |
Prior stem cell transplant | |||||||
  Yes | 21 | 0 | 33 | 10 | 5 | 5 | 0 |
  No | 110 | 7 | 21 | 22 | 6 | 6 | 5 |
Prior monoclonal antibody therapyc | |||||||
  Yes | 20 | 20d | 35 | 50e | 5 | 5 | 0 |
  No | 111 | 4d | 21 | 14e | 5 | 5 | 5 |
Bone marrow involvement | |||||||
  Yes | 37 | 8 | 30 | 24 | 5 | 5 | 0 |
  No | 94 | 5 | 20 | 18 | 5 | 5 | 5 |